Vanguard Group Inc. Grows Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Vanguard Group Inc. increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 3.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,281,714 shares of the biopharmaceutical company's stock after buying an additional 386,618 shares during the quarter. Vanguard Group Inc. owned 10.44% of Halozyme Therapeutics worth $634,999,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HALO. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $29,000. CBIZ Investment Advisory Services LLC bought a new position in Halozyme Therapeutics during the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC boosted its stake in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new position in Halozyme Therapeutics during the fourth quarter worth $69,000. Finally, Parkside Financial Bank & Trust lifted its holdings in Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 322 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeffrey William Henderson sold 503 shares of the firm's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total transaction of $32,217.15. Following the sale, the director now owns 33,108 shares of the company's stock, valued at $2,120,567.40. This trade represents a 1.50 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,200 shares of company stock valued at $1,786,668. Corporate insiders own 2.90% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

HALO has been the topic of a number of recent analyst reports. Piper Sandler boosted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Wells Fargo & Company lowered their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Benchmark reaffirmed a "buy" rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $62.78.

Halozyme Therapeutics Stock Down 3.5 %

HALO traded down $2.15 during midday trading on Friday, reaching $59.77. 2,295,325 shares of the company were exchanged, compared to its average volume of 1,392,933. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $66.00. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The company's fifty day moving average price is $59.82 and its 200 day moving average price is $54.93. The company has a market cap of $7.38 billion, a price-to-earnings ratio of 17.43, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.